Welcome to our dedicated page for Procept Biorobotics news (Ticker: PRCT), a resource for investors and traders seeking the latest updates and insights on Procept Biorobotics stock.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. News about PROCEPT BioRobotics frequently centers on its AQUABEAM and HYDROS Robotic Systems, which deliver Aquablation therapy for benign prostatic hyperplasia (BPH) and are being evaluated in clinical studies for localized prostate cancer.
Investors and clinicians following PRCT news can expect regular updates on quarterly financial results, revenue guidance, and operating metrics such as U.S. system placements, handpiece and consumable revenue, and international performance. The company issues detailed earnings press releases and hosts conference calls and webcasts to discuss its results and outlook.
Company news also covers clinical and regulatory milestones. Examples include progress in the WATER IV Prostate Cancer Trial, which compares Aquablation therapy with radical prostatectomy, and developments related to reimbursement, such as the assignment of a Category I CPT code for Aquablation therapy in the Medicare Proposed Physician Fee Schedule. These items provide insight into how the therapy is being integrated into clinical practice and payment systems.
Additional PRCT headlines highlight participation in healthcare and investor conferences, executive leadership updates, and commentary on the growing body of peer-reviewed publications supporting Aquablation therapy. For anyone tracking the evolution of robotic urology treatments, the PROCEPT BioRobotics news feed offers a centralized view of financial performance, clinical research, reimbursement changes, and corporate events related to Aquablation therapy and the company’s robotic platforms.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) has appointed Elisabeth Sandoval to its Board of Directors, expanding the board to nine members. Sandoval brings extensive experience from her roles at Alder Biopharmaceuticals and Allergan, emphasizing her commercial expertise in healthcare. CEO Reza Zadno stated that her background aligns with the company's strategies to enhance adoption of Aquablation therapy for treating benign prostatic hyperplasia (BPH). This therapy aims to revolutionize care for the 40 million men in the U.S. affected by BPH, supported by a strong body of clinical evidence.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) will report its third-quarter 2021 financial results on November 4, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, accessible via phone or webcast. The company specializes in urological surgical robotics, focusing on the AquaBeam Robotic System, which treats benign prostatic hyperplasia (BPH), affecting approximately 40 million men in the U.S. PROCEPT has established a robust clinical foundation with nine studies and over 100 peer-reviewed publications supporting its Aquablation therapy.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced that Cigna will now cover Aquablation therapy for Benign Prostatic Hyperplasia (BPH), effective September 15, 2021. This decision enhances access to a proven treatment option for millions of Cigna members suffering from lower urinary tract symptoms (LUTS) due to BPH. CEO Reza Zadno emphasized that Aquablation therapy, which has demonstrated clinical efficacy irrespective of prostate size or shape, aligns with high-quality clinical data trusted by payors. Cigna joins Medicare and other private health plans in supporting this therapy.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) has successfully closed its upsized initial public offering of 7,539,400 shares at a price of $25.00 per share, generating approximately $188.5 million in gross proceeds. This offering included the full exercise of underwriters' options for an additional 983,400 shares. Shares began trading on the Nasdaq Global Market on September 15, 2021. The offering was managed by BofA Securities and Goldman Sachs, among others. PROCEPT focuses on innovative solutions in urology, particularly the AquaBeam Robotic System for treating benign prostatic hyperplasia (BPH).
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) has priced its upsized initial public offering at $25.00 per share, raising total gross proceeds of $163.9 million. The offering consists of 6,556,000 shares, all sold by PROCEPT, with trading on the Nasdaq expected to begin on September 15, 2021. The offering is scheduled to close on September 17, 2021, pending customary conditions. Underwriters have a 30-day option to purchase an additional 983,400 shares. PROCEPT is focused on developing robotic solutions for urology, particularly the AquaBeam Robotic System for treating benign prostatic hyperplasia.